AI pathology meets spatial omics: Decoding tissue architecture for biomarkers
Heres whats covered in this post: The GLP-1 drugs and muscle loss problem what the data actually shows, and why the internet panic is both overblown and underblown in different ways What myostatin is the protein that limits muscle growth, and why scientists have spent 30 years trying to block it Two drugs, two philosophies apitegromab versus bimagrumab, the precision approach versus the heavy hand, and their very different risk profiles The EMBRAZE trial the most exciting recent result, and the critical finding the headlines skipped A brief word on retatrutide the most powerful GLP-1-class drug yet, and a caution worth noting Why a lean, healthy 34-year-old doctor takes low-dose tirzepatide Dr
Efficacy and tolerability of -galactosidase in treating gas-related symptoms in children: a randomized, double-blind, placebo-controlled trial
At SemaPen, we're part of Phoenix Health, one of the UK's most trusted bariatric surgery providers
Averaging the indicator maps, weighted by sample size, yielded a density of effects map across studies (Figure 2, Panel b
.webp)
